Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd
Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd engages in the wholesale and retail of pharmaceuticals products in China. It provides raw materials, biological products, chemical drugs, Chinese herbal medicines, medical devices, and other products. The company also offers Chinese patent medicines in the form of granules, capsules, particles, tablets, slices, and pills; foods, such as beverages… Read more
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) - Net Assets
Latest net assets as of June 2025: CN¥1.86 Billion CNY
Based on the latest financial reports, Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) has net assets worth CN¥1.86 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.56 Billion) and total liabilities (CN¥4.70 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.86 Billion |
| % of Total Assets | 28.34% |
| Annual Growth Rate | 13.59% |
| 5-Year Change | 77.52% |
| 10-Year Change | N/A |
| Growth Volatility | 23.1 |
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (2019–2024)
The table below shows the annual net assets of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.85 Billion | +3.76% |
| 2023-12-31 | CN¥1.78 Billion | -1.96% |
| 2022-12-31 | CN¥1.82 Billion | +8.22% |
| 2021-12-31 | CN¥1.68 Billion | +61.24% |
| 2020-12-31 | CN¥1.04 Billion | +6.57% |
| 2019-12-31 | CN¥977.24 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 64.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥561.18 Million | 31.94% |
| Other Components | CN¥1.20 Billion | 68.06% |
| Total Equity | CN¥1.76 Billion | 100.00% |
Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd Competitors by Market Cap
The table below lists competitors of Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Touchstone International Medical Science Co Ltd
SHG:688013
|
$174.48 Million |
|
Thai Credit Pcl
BK:CREDIT
|
$174.53 Million |
|
Total Gabon
F:RZW
|
$174.54 Million |
|
XiAn Catering Co Ltd
SHE:000721
|
$174.55 Million |
|
DITTO (THAILAND)
BK:DITTO-R
|
$174.47 Million |
|
Wuhan Tianyu Info Industry
SHE:300205
|
$174.42 Million |
|
Northern United Publishing & Media Group Co Ltd
SHG:601999
|
$174.35 Million |
|
Electricite de Strasbourg S.A.
LSE:0J74
|
$174.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,747,230,887 to 1,756,782,100, a change of 9,551,212 (0.5%).
- Net income of 26,574,897 contributed positively to equity growth.
- Dividend payments of 92,350,575 reduced retained earnings.
- Other factors increased equity by 75,326,890.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥26.57 Million | +1.51% |
| Dividends Paid | CN¥92.35 Million | -5.26% |
| Other Changes | CN¥75.33 Million | +4.29% |
| Total Change | CN¥- | 0.55% |
Book Value vs Market Value Analysis
This analysis compares Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.88x to 1.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥6.31 | CN¥11.88 | x |
| 2020-12-31 | CN¥6.72 | CN¥11.88 | x |
| 2021-12-31 | CN¥8.13 | CN¥11.88 | x |
| 2022-12-31 | CN¥8.34 | CN¥11.88 | x |
| 2023-12-31 | CN¥8.46 | CN¥11.88 | x |
| 2024-12-31 | CN¥8.55 | CN¥11.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.51%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 3.52x
- Recent ROE (1.51%) is below the historical average (4.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 8.97% | 3.57% | 1.22x | 2.06x | CN¥-10.07 Million |
| 2020 | 6.23% | 2.77% | 1.06x | 2.11x | CN¥-39.29 Million |
| 2021 | 4.07% | 2.63% | 0.87x | 1.78x | CN¥-99.66 Million |
| 2022 | 2.97% | 1.55% | 0.84x | 2.28x | CN¥-121.16 Million |
| 2023 | 1.96% | 0.88% | 0.74x | 3.02x | CN¥-140.42 Million |
| 2024 | 1.51% | 0.51% | 0.85x | 3.52x | CN¥-149.10 Million |
Industry Comparison
This section compares Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $2,081,482,913
- Average return on equity (ROE) among peers: 9.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hunan Dajiaweikang Pharmaceutical Industry Co.Ltd (301126) | CN¥1.86 Billion | 8.97% | 2.53x | $174.48 Million |
| Cachet Pharmaceutical Co Ltd (002462) | $4.92 Billion | 13.40% | 1.65x | $437.62 Million |
| Yunnan Hongxiang Yixintang (002727) | $497.43 Million | 20.70% | 1.22x | $545.21 Million |
| Luyan Pharma Co Ltd (002788) | $746.00 Million | 15.21% | 3.60x | $450.11 Million |
| Ji Yao Holding Group Co Ltd (300108) | $-366.31 Million | 0.00% | 0.00x | $18.23 Million |
| Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co. Ltd. (300937) | $856.04 Million | 6.95% | 0.97x | $170.91 Million |
| ShuYu Civilian Pharmacy Corp. Ltd. (301017) | $2.27 Billion | 10.12% | 2.47x | $188.58 Million |
| Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A (301408) | $1.98 Billion | 5.80% | 1.33x | $323.73 Million |
| Shanghai No1 Pharmacy Co Ltd (600833) | $736.00 Million | 6.25% | 0.61x | $180.65 Million |
| Laobaixing Pharmacy (603883) | $7.10 Billion | 11.06% | 2.01x | $739.96 Million |